Review

Microbial factories for recombinant pharmaceuticals

Neus Ferrer-Miralles^1,2,3 , Joan Domingo-Espín^1,2,3 , José Luis Corchero^3,1 , Esther Vázquez^1,2,3 and Antonio Villaverde^1,2,3

¹  Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain

²  Department de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain

³  CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain

author email corresponding author email

Microbial Cell Factories 2009, 8:17doi:10.1186/1475-2859-8-17

Published:	24 March 2009

Abstract

Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for human use by the Food and Drug Administration (FDA) and/or by the European Medicines Agency (EMEA) are microbial cells, either bacteria or yeast. This fact indicates that despite the diverse bottlenecks and obstacles that microbial systems pose to the efficient production of functional mammalian proteins, namely lack or unconventional post-translational modifications, proteolytic instability, poor solubility and activation of cell stress responses, among others, they represent convenient and powerful tools for recombinant protein production. The entering into the market of a progressively increasing number of protein drugs produced in non-microbial systems has not impaired the development of products obtained in microbial cells, proving the robustness of the microbial set of cellular systems (so far Escherichia coli and Saccharomyces cerevisae) developed for protein drug production. We summarize here the nature, properties and applications of all those pharmaceuticals and the relevant features of the current and potential producing hosts, in a comparative way.